TrialNature communications2023

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Laurence Buisseret et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.